Introduced
by
To require Blue Cross/Blue Shield health policies to include coverage for "off-label" drug use to treat serious or life-threatening conditions. “Off-label” use is defined as “the use of a drug for clinical indications other than those stated in the labeling approved by the federal Food and Drug Administration.” The bill specifies certain conditions which would make a particular “off-label” use qualify, such as being recognized by the American Medical Association, being the subject of two or more peer-reviewed medical articles with no contradictory evidence, and others.
Referred to the Committee on Health Policy
Substitute offered
To replace the previous version of the bill with a version recommended by the committee which reported it. The substitute incorporates technical changes resulting from committee testimony and deliberation. These changes do not affect the substance of the bill as previously described.
The substitute passed by voice vote
Amendment offered
by
To establish a time frame on which the bill will go into effect if passed.
The amendment passed by voice vote
Amendment offered
by
To clarify a technical provision in the bill related to the drug payment approval process of health plans.
The amendment passed by voice vote
Amendment offered
by
To establish that the drug uses authorized by the bill could not be subject to different deductibles or sanctions as a other drugs covered by an insurance plan.
The amendment passed by voice vote
Passed in the Senate 36 to 0 (details)
To require Blue Cross/Blue Shield health policies to include coverage for "off-label" drug use to treat serious or life-threatening conditions. “Off-label” use is defined as “the use of a drug for clinical indications other than those stated in the labeling approved by the federal Food and Drug Administration.” The bill specifies certain conditions which would make a particular “off-label” use qualify, such as being recognized by the American Medical Association, being the subject of two or more peer-reviewed medical articles with no contradictory evidence, and others.
Passed in the House 103 to 0 (details)
